Atlas Trials

Harboring EGFR Sensitive Mutations NSCLC

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Harboring EGFR Sensitive Mutations NSCLC

RecordFirmDate
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations (NCT06735391)Shanghai JMT-Bio Inc.2024-10-23

Track Harboring EGFR Sensitive Mutations NSCLC automatically

Every clearance here is in the API, with alerts when new ones post.